Smartkarma Originals
IPO Analytics: Cut Your Losses and Let Your Profits Run, Holds True for IPOs
Since inception of our IPO research in 2015, the Aequitas Research team has covered over 361 IPOs, which raised over US$100m each, across Asia...
1.7k Views
CStone Pharma IPO Preview: Mixed Prospects of Late-Stage Clinical Drug Candidates
CStone Pharma (CSTONE HK) is a biopharmaceutical company which is developing a pipeline of 14 drug candidates of which 9 are in clinical...
669 Views
CStone Pharma (基石药业) IPO: Strong Assembly and Backing (Part 1)
CStone Pharma is raising up to USD 400 million via a listing on the Hong Kong Stock Exchange. In this insight, we will discuss the following...
876 Views
2018 HK-Connect SouthBound In a Nutshell
Since autumn of 2014, the HK-Shanghai Connect, and later the HK-Shenzhen Connect mechanisms have provided means for mainland investors to buy Hong...
700 Views
WuXi Biologics – The Foxconn or Qualcomm of Global CDMO?
During the first week of 2019, we visited Wuxi Biologics (Cayman) Inc (2269 HK) headquarters in Shanghai, as well as spend time touring the lab....
859 Views